BMO Capital analyst Evan Seigerman says high-dose Spinraza approval and positive Phase 2 AMETHYST trial data are both “likely positive drivers” of Biogen (BIIB) shares. The firm has a Market Perform rating and $196 price target on Biogen shares, which are up $3.37, or 2%, to $187.21 in early Monday trading.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen announces FDA approval of high dose regimen of Spinraza
- Biogen (Litifilimab/Lupus): Encouraging Early Data but Competitive and Clinical Risks Support a Neutral Hold
- Balanced but Constrained Upside: Hold Rating on Biogen as Modest Litifilimab Data Meet Rising Lupus Competition
- Biogen announces AMETHYST Part A met primary endpoint with litifilimab
- Biogen Advances Litifilimab Delivery Study, Sharpening Its Autoimmune Launch Strategy